- Home
- MDGL vs NCLH Comparison
MDGL vs NCLH Comparison
Compare MDGL & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | NCLH |
|---|---|---|
| Founded | 2011 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.7B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | MDGL | NCLH |
|---|---|---|
| Price | $476.87 | $23.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | ★ $631.46 | $27.78 |
| AVG Volume (30 Days) | 302.4K | ★ 20.3M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | N/A | ★ 1.40 |
| Revenue | $740,640,000.00 | ★ $9,692,558,000.00 |
| Revenue This Year | $435.42 | $6.84 |
| Revenue Next Year | $54.39 | $10.00 |
| P/E Ratio | ★ N/A | $16.35 |
| Revenue Growth | ★ 864.21 | 3.59 |
| 52 Week Low | $265.00 | $14.21 |
| 52 Week High | $615.00 | $27.65 |
Technical Indicators
Market Signals| Indicator | MDGL | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 58.32 |
| Support Level | $458.00 | $21.38 |
| Resistance Level | $486.88 | $23.40 |
| Average True Range (ATR) | 19.28 | 1.06 |
| MACD | 0.70 | 0.15 |
| Stochastic Oscillator | 40.73 | 91.20 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.